Form 4: Xeris Biopharma COO Sells Shares for Tax Obligations

Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch disposed of 733 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., reported a transaction on October 2, 2025.
• The transaction involved the disposition of 733 shares of Common Stock at a price of $8.31 per share.
• These shares were withheld by the Issuer to satisfy income tax and withholding obligations related to the net settlement of restricted stock units that vested on October 2, 2025.
• Following this transaction, Kevin McCulloch directly beneficially owns 1,700,426 shares of Common Stock.
• Additionally, 25,000 shares are indirectly beneficially owned by his spouse, for which the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction for tax withholding purposes, which is neutral in terms of company performance or future outlook.

Positives

• The transaction is a routine administrative event related to the vesting of restricted stock units, indicating the fulfillment of performance or tenure conditions for the executive.

Negatives

• The disposition, while non-discretionary, results in a slight reduction of direct insider ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a common occurrence in publicly traded companies when executive compensation includes restricted stock units that vest over time. The disposition of shares for tax withholding is a standard administrative process and does not typically reflect a discretionary investment decision by the insider.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction and does not signal a change in management's confidence or company fundamentals.
• Employees: The vesting of restricted stock units indicates the executive has met certain conditions, which can be a positive for employee retention and alignment with company goals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an executive to cover tax liabilities associated with vested restricted stock units. It provides no new fundamental information about Xeris Biopharma Holdings, Inc.'s operational performance, strategic direction, or financial health. Therefore, it does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate for investors based solely on this filing.

Keywords

Xeris Biopharma Holdings, XERS, Kevin McCulloch, Insider Transaction, Form 4, Restricted Stock Units, Tax Withholding, Common Stock